Investor Overview

Corporate Profile


Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, including glaucoma. In July 2017, the Company announced top-line results of its Phase 2 fixed-dose combination trial of trabodenoson and latanoprost for the treatment of glaucoma. The trial did not meet its primary efficacy endpoint and the Company has since discontinued development of trabodenoson in order to focus on evaluating strategic alternatives.... Read More >

Stock Information

NASDAQ :  ITEK (Common Stock)
$2.57
 + 0.09 (3.63%)
Data as of 12/08/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minute delay
Refresh quote
Stock chart for: ITEK.OQ.  Currently trading at $2.57 with a 52 week high of $7.40 and a 52 week low of $0.85.